Abstract: Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms,R.sub.2 is H or an acyl group having 1-12 carbon atoms andR.sub.3 is C, N--CH.sub.3 or a direct bond;and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non- or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favorable neuromuscular blocking agents.

Abstract: 2.beta.,16.beta.-diamino-3.alpha.,17.alpha.-oxygenated androstanes having one quaternized group, process for the preparation of these compounds and pharmaceutical compositions comprising such compounds as the active ingredient. The aforementioned compounds are favourable neuro-muscular blocking agents.

Abstract: The present invention relates to novel biologically active tricyclic compounds, of the general formula I: ##STR1## and salts thereof, in which R.sub.1 represents hydrogen, alkyl of 1-6 carbon atoms, an optionally substituted aralkyl group or an acyl group,R.sub.2 represents hydrogen, alkyl (1-6 C), or an optionally substituted aralkyl group, orR.sub.1 +R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, p1 X and Y each represent hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, CF.sub.3 or an acyloxy group, andthe dotted line signifies an optional extra bond.The compounds of the general formula I have valuable anti-depressant activity without a sustained influence on appetite.

Abstract: The invention concerns novel anti-arrhythmic amino-alcohol derivatives, characterized by the general formula (1) ##STR1## or pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2 and R.sub.3 each independently represent hydrogen, alkyl having 1-6 carbon atoms, alkoxy having 1-6 carbon atoms, acyloxy having 1-6 carbon atoms, hydroxy, halogen or optionally alkyl-substituted amino;R.sub.4 represents hydrogen, hydroxy or alkyl having 1-6 carbon atoms,R.sub.5 represents hydrogen or alkyl having 1-6 carbon atoms,R.sub.6 represents hydrogen, acyl having 1-18 carbon atoms or alkyl having 1-6 carbon atoms,R.sub.7 and R.sub.8 each independently represent hydrogen or alkyl having 1-6 carbon atoms,X represents a direct bond or an oxygen atom, andn and m each independently are integers having a value of 1 or 2, whereby the sum of n and m is 2 or 3.

Abstract: The present invention relates to the use of a compound of the general formula I ##STR1## wherein R.sub.1 and R.sub.2 represent hydrogen or a lower alkyl group (1-4 C), preferably methyl, ethyl, propyl or isopropyl, the broken line indicates an optional extra bond, and X and Y represent hydrogen, alkyl (1-4 C) or halogen (preferably fluorine), or a pharmaceutically acceptable acid addition salt thereof, for its anti-convulsive property.

Abstract: This invention relates to novel mono- and bisquaternary ammonium derivatives of 5.alpha.-androstanes having the formula: ##STR1## wherein: R.sub.1 =H or alkyl (1-4 C);R.sub.2 and R.sub.3 each are alkyl (1-4 C) or form together with the N-atom a piperidino, pyrrolidino or morpholino group;R.sub.4 =O or H(.beta.OR.sub.5) andR.sub.5 =H or acyl derived from an organic carboxylic acid having 1-18, preferably 1-6 carbon atoms;the quaternarizing group being a saturated or unsaturated aliphatic hydrocarbon group having 1-4 carbon atoms the anion being halide; and acid addition salts of the monoquaternary compounds; and to pharmaceutical preparations containing one or more of said androstane compounds as active constituent.The compounds according to the invention are non-depolarizing neuromuscular blocking agents having very quick onset and recovery characteristics, a short duration of action and a favorable dissociation between muscle blocking and vagal blocking effects.

Abstract: New and pharmacologically useful 17-amino-16-hydroxy-steroids of the androstane and oestrane series are disclosed having the formula I: ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, wherein:R.sub.1 =H or hydrocarbyl of one to six carbon atoms (preferably lower alkyl, such as methyl);R.sub.2 =H or hydrocarbyl of one to six carbon atoms (preferably lower alkyl, such as methyl);R.sub.3 =a free, esterified or etherified hydroxyl group;ring A inclusive carbon atoms 6 and 9 has one of the following configurations: ##STR2## in which R.sub.4 =a free, esterified or etherified hydroxyl group;R.sub.5 =O or H(R.sub.7), wherein R.sub.7 is a free, esterified or etherified hydroxyl group;R.sub.6 =H or methyl; andthe dotted lines represent an optional double bond in 4,5- or 5,6-position;as well as the enantiomers and racemates of these steroids.The novel compounds have antiarrhythmic properties.

Abstract: The present invention relates to novel biologically active tricyclic compounds of the general formula: ##STR1## and salts thereof, in whichR.sub.1 and R.sub.2 stand for hydrogen, alkyl or alkenyl, an optionally substituted aralkyl group or an acyl group orR.sub.1 +R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, andX and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, trifluoromethyl or an acyloxy group,which compounds have valuable biological activities, particularly anorectic activity.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-monoquaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters or the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Abstract: The present invention relates to novel biologically active tricyclic compounds of the general formula: ##STR1## and salts thereof, in whichR.sub.1 and R.sub.2 stand for hydrogen, alkyl or alkenyl, an optionally substituted aralkyl group or an acyl group orR.sub.1 +R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, andX and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, trifluoromethyl or an acyloxy group,which compounds have valuable biological activities, particularly anorectic activity.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-mono-quaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3-.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters of the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Abstract: The present invention relates to novel benzo(b) bicyclo[3.3.1]nones of the general formula I: ##STR1## and a salt or nitrogen oxide thereof, in which R.sub.1 and R.sub.2 stand for hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, an optionally substituted aralkyl group or an acyl group orR.sub.1 and R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ringR.sub.3 is a free, etherified or esterified hydroxy,X and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 C-atoms, nitro, CF.sub.3 or an acyloxy group, having valuable biological activities, particularly anorectic activity.